PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.31%
Revenue growth under 50% of 3088.T's 65.47%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
2.91%
Gross profit growth under 50% of 3088.T's 71.46%. Michael Burry would be concerned about a severe competitive disadvantage.
7.71%
EBIT growth below 50% of 3088.T's 42.48%. Michael Burry would suspect deeper competitive or cost structure issues.
7.71%
Operating income growth under 50% of 3088.T's 42.48%. Michael Burry would be concerned about deeper cost or sales issues.
4.16%
Net income growth under 50% of 3088.T's 262.78%. Michael Burry would suspect the firm is falling well behind a key competitor.
4.15%
EPS growth under 50% of 3088.T's 196.65%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
4.15%
Diluted EPS growth under 50% of 3088.T's 196.67%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.83%
10Y revenue/share CAGR under 50% of 3088.T's 106.58%. Michael Burry would suspect a lasting competitive disadvantage.
51.99%
5Y revenue/share CAGR at 75-90% of 3088.T's 67.73%. Bill Ackman would encourage strategies to match competitor’s pace.
23.42%
3Y revenue/share CAGR under 50% of 3088.T's 56.33%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.42%
Below 50% of 3088.T's 615.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
33.73%
Below 50% of 3088.T's 232.82%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
23.99%
Below 50% of 3088.T's 152.78%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
167.66%
10Y equity/share CAGR at 50-75% of 3088.T's 320.37%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
110.15%
5Y equity/share CAGR at 50-75% of 3088.T's 160.06%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
52.73%
Below 50% of 3088.T's 129.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.78%
3Y dividend/share CAGR of 77.78% while 3088.T is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
14.05%
AR growth is negative/stable vs. 3088.T's 126.44%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-0.11%
Inventory is declining while 3088.T stands at 62.75%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.78%
Negative asset growth while 3088.T invests at 75.57%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
2.01%
Under 50% of 3088.T's 87.91%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-7.70%
We’re deleveraging while 3088.T stands at 2.51%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.88%
SG&A declining or stable vs. 3088.T's 78.18%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.